title: Efficacy of high-dose palliative radiotherapy for localised, castration-resistant prostate cancer.
abstract: OBJECTIVE
  There are limited outcome data after radiotherapy treatment for clinically localised, castration-resistant prostate cancer. We report our single institution experience on patient outcomes in this group using high-dose palliative radiotherapy (HDPRT).
  
  
  METHODS
  A retrospective review of patient hospital records was conducted in prostate cancer patients treated with palliative intent radiotherapy and restricted to those who had castration-resistant disease, no evidence of regional or distant disease and who received a local radiotherapy dose equivalent to 40 Gy or greater.
  
  
  RESULTS
  Fifty-one patients met the study criteria, 88% of these had high-risk disease at initial diagnosis. The median time to delivery of HDPRT was 66 months and the median follow-up from HDPRT was 54 months. Grade 3 or worse toxicity was experienced in 8%. The estimated freedom from local failure, cause-specific survival and overall survival at 5 years were 81, 65 and 35%, respectively. Local procedures were a significant contributor to local morbidity, with the most common procedure a transurethral resection of the prostate (27% patients). Only two patients died from complications of local failure.
  
  
  CONCLUSIONS
  HDPRT was well tolerated and provided a high rate of local control in a clinically localised castration-resistant prostate cancer population. Although prostate cancer remained the most frequent cause of death, some patients had extended survival without evidence of disease progression.
authors.affiliation: Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Electronic address: rohenwhite@hotmail.com.
authors.forename: R
authors.initials: R
authors.lastname: White
authors.affiliation: Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
authors.forename: R
authors.initials: R
authors.lastname: Khor
authors.affiliation: Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
authors.forename: M
authors.initials: M
authors.lastname: Bressel
authors.affiliation: Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia; Department of Biochemistry, Monash University, Melbourne, VIC, Australia; Department of Medical Radiations, Monash Univeristy, Melbourne, VIC, Australia.
authors.forename: G
authors.initials: G
authors.lastname: Duchesne
authors.affiliation: Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
authors.forename: S
authors.initials: S
authors.lastname: Williams
authors.affiliation: Radiation Oncology, Epworth Healthcare, Melbourne, VIC, Australia.
authors.forename: P
authors.initials: P
authors.lastname: Bowden
authors.affiliation: Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
authors.forename: K
authors.initials: K
authors.lastname: Tai
authors.affiliation: Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
authors.forename: F
authors.initials: F
authors.lastname: Foroudi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D008297:Male; D008875:Middle Aged; D010166:Palliative Care / Q000379:methods*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D017211:Treatment Failure; D016896:Treatment Outcome
keywords: Castration-resistant prostate cancer; palliative; radiotherapy